Galmed Pharmaceuticals Ltd. (GLMD) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Galmed Pharmaceuticals Ltd. (GLMD) Bundle
Gain insight into your Galmed Pharmaceuticals Ltd. (GLMD) valuation analysis using our state-of-the-art DCF Calculator! Preloaded with real GLMD data, this Excel template empowers you to adjust forecasts and assumptions to accurately determine Galmed Pharmaceuticals Ltd.'s intrinsic value.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -22.3 | -30.2 | -32.8 | -17.6 | -6.9 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -22.4 | -30.2 | -32.9 | -17.7 | -6.9 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | 75.5 | 50.9 | 34.8 | 13.8 | 12.6 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .2 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | -27.9 | -3.8 | -.9 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | 6.0 | 7.0 | 4.9 | 2.6 | 1.9 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -20.3 | -29.0 | -32.4 | -18.3 | -6.9 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | 13.7 | -52.1 | -37.4 | -21.7 | -7.6 | -1.7 | .0 | .0 | .0 | .0 |
WACC, % | 9.08 | 9.16 | 9.2 | 9.22 | 9.22 | 9.18 | 9.18 | 9.18 | 9.18 | 9.18 |
PV UFCF | ||||||||||
SUM PV UFCF | -1.6 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -2 | |||||||||
Net Debt | -3 | |||||||||
Equity Value | 1 | |||||||||
Diluted Shares Outstanding, MM | 0 | |||||||||
Equity Value Per Share | 5.42 |
What You Will Get
- Real GLMD Financial Data: Pre-filled with Galmed Pharmaceuticals’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Galmed Pharmaceuticals’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- 🔍 Real-Life GLMD Financials: Pre-filled historical and projected data for Galmed Pharmaceuticals Ltd.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Galmed’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Galmed’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the pre-prepared Excel file containing Galmed Pharmaceuticals Ltd.'s (GLMD) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare the results.
- Make Decisions: Leverage the valuation outcomes to inform your investment choices.
Why Choose Galmed Pharmaceuticals Ltd. (GLMD) Calculator?
- Accuracy: Utilizes real Galmed financial data for precise calculations.
- Flexibility: Tailored for users to easily adjust and experiment with inputs.
- Time-Saving: Avoid the complexities of creating a financial model from the ground up.
- Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
- User-Friendly: Intuitive interface designed for all users, regardless of financial modeling skills.
Who Should Use This Product?
- Pharmaceutical Students: Explore drug development processes and apply them using real market data.
- Researchers: Integrate advanced models into studies or academic projects related to drug efficacy.
- Investors: Validate your investment strategies and assess valuation scenarios for Galmed Pharmaceuticals (GLMD).
- Market Analysts: Enhance your analysis with a ready-to-use, customizable financial model tailored for biotech firms.
- Entrepreneurs: Understand how large pharmaceutical companies like Galmed Pharmaceuticals (GLMD) are evaluated in the market.
What the Template Contains
- Historical Data: Includes Galmed Pharmaceuticals Ltd.’s (GLMD) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Galmed Pharmaceuticals Ltd.’s (GLMD) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Galmed Pharmaceuticals Ltd.’s (GLMD) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.